Kisqali is currently a blockbuster breast cancer medicine for Novartis in late stage breast cancer. Check out the wide range of physician opinions regarding the NATALEE trial studying Kisqali in early stage breast cancer. How will the FDA decide later this year on this potential

Dr. Julia Rotow MD at #ASCO24 leads a thoughtful discussion of refining adjuvant therapy and deciphering the data presented on adjuvant icotinib (does subsequent therapy impact lack of difference in 6m and 12m?) and MRD (does chemo impact sensitivity? how do we apply the data?)

Dr. Tina Cascone gives an important update on CheckMate 77T at the #ASCO24 oral abstract session. CheckMate 77T was a phase III study showing the addition of perioperative nivolumab to neoadjuvant chemo for resectable stage II/III NSCLC improved both EFS & pCR. Here, N2+ subset.

⭐️ Making mom and dad proud ⭐️ Thank you for investing in me! From Porto Alegre to the world 🌎Moffitt Cancer Center Moffitt Research Dr. Patrick Hwu 🇧🇷 “Conheça as estrelas do Moffitt” Orgulhando mãe e pai 🥹 🫶🏼Valeu o investimento! De Porto Alegre pro 🌎 #ASCO24

⭐️Goose Bumps and a Standing Ovation ASCO is a magical experience. ❤️ talking to Dr. Suresh S. Ramalingam, MD, FASCO about his 1st patient with EGFRm over ten years ago to his plenary session yesterday. 👇Join us tonight on OncLive.com #ASCO24 globalmeet.webcasts.com/starthere.jsp?… We discussed the LAURA study

100/10 recommendation: Attending ASCO poster sessions with your medical oncology friends #ASCO24

The largest NSCLC dataset analyzed for biomarker distribution across histologies, sufficient enough prevalence across LUAD and ASC to be included in WHO for lung tumors, and provides reassurance that NOS, LCC and sarcomatoid cases must be considered for biomarker workup #ASCO24

🔥 Hot takes on ADAURA Trial from #ASCO23 🎙️ADAURA Sentiment Analysis hubs.ly/Q02KHXh70💡Is it a game-changer or are we missing the mark? Dive into the debate & share your thoughts! 🧬💊 #oncology #medicalresearch #ASCO2023

#ICYMI: The treatment landscape for patients with resectable NSCLC has changed! My newly updated slide for our fellows. OncoAlert #lcsm #WCLC24

Are you prepared for the World Congress on Lung Cancer Meeting this weekend? Do you know the backstory of the plenary session HARMONI-2 clinical trial? Are the Robinhooders ready to go📈 $SMMT 👉The Wild West of World Lung Cancer #WCLC24 hubs.ly/Q02NY2tm0

Will Summit Therapeutics $SMMT HARMONI-2 Clinical Trial data displace Merck Keytruda as the king of Lung Cancer Therapy? #WCLC24 Follow the interesting backstory on this Plenary Session topic for Sunday's Meeting. #LCSM

KEYNOTE-522 Sentiment Analysis and Key Opinion Leader Discussion including #ESMO24👉KEYNOTE-522 Clinical Trial Sentiment hubs.ly/Q02PWXtN0

CONTACT-02 was a major clinical trial presented at #ESMO24. KOL sentiments were all over the map for this trial. What did the KOLs say and how did their sentiments differ? Check it out with the use of Artificial Intelligence 👉CONTACT-02 AI Chatbot kolpulse.com/contact-clinic…

IMROZ Clinical Trial Sentiment hubs.ly/Q02QGZMC0 grants FDA Approval based on IMROZ clinical trial. Read what Myeloma Experts think of this clinical trial by Sanofi

The FDA just approved SARCLISA® (isatuximab-irfc) quad therapy for newly diagnosed multiple myeloma. Read Key Opinion Leader Sentiment regarding this important trial. #mmsm #ASCO24 IMROZ Clinical Trial Sentiment hubs.ly/Q02QGr3P0

The U.S. FDA just granted approval to SARCLISA® (isatuximab-irfc) from Sanofi US based on the IMROZ clinical trial. Find out what thought leaders in myeloma think of this trial with this interactive AI Chatbot👉IMROZ AI Chatbot hubs.ly/Q02QG-Wv0 #mmsm #asco24 #medtwitter

#Myeloma Paper of the Day: Study of most common symptomatic adverse reactions of cancer treatments from US drug labels (2015-2021) to inform selection of patient-reported outcomes finds cough was common (50%) in multiple myeloma: pubmed.ncbi.nlm.nih.gov/39389354/. #mmsm

5yr outcomes Ph II NADIM trial: - 5yr PFS 65% OS 69.3% - pCR: 5yr PFS 92% OS 95.8%; nonpCR 60%&66% - ctDNA clearance: 5yr PFS 85.2% OS 92.3% ‘pts disease-free beyond 3yrs, could be considered cured’ Powerful conclusion, powerful trial M.Provencio thelancet.com/journals/lanon…

🚨 BIG NEWS 🚨 Press Release: Addition of Lurbinectedin to Atezolizumab maintenance ➡️ Significant improvement in OS and PFS! Phase 3 IMforte trial ES-SCLC 1L maintenance Atezo + lurbinectedin ⬆️PFS ✅ ⬆️OS ✅ NDA➡️2025 #LCAM #SCLC SmallCellSMASHERS investor.jazzpharma.com/news-releases/…

You know who you are, we all do. ☠️🤡👀 #MedTwitter